Jonathan Lim, MD, Chairman and CEO of Ignyta, Inc. discusses what’s next for entrectinib and his hopes to launch the drug globally in the next couple of years. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Advertisement
[the_ad id="32629"]